fda drug safety communication semaglutide naion 2025 The sent a warning letter to the maker of Ozempic and Wegovy over unreported potential GLP-1 side effects. Here's what to know Semaglutide linked to increased risk

Maryland Trim Clinic (MTC) in Laurel, MD For patients exploring medically supervised weight management options, Maryland Trim Clinic in Laurel, MD offers support focused on personalized metabolic and wellness care

Digoxin concentrations are reduced when Rybelsus and digoxin are used together

Semaglutide is a GLP-1 receptor agonist originally developed for blood sugar regulation in type 2 diabetes

As the FDA has cautioned, unapproved compounded semaglutide drugs do not have the same safety, quality, and effectiveness assurances as Novo Nordisks FDA-approved semaglutide medicines, and patients should not use a compounded drug if an approved drug is available. Theres huge safety implications, Ryder says

3163) was created in December 2025 for claims that Ozempic use caused NAION (an eye stroke that can cause vision loss)